Background & Aims-The drug-induced liver injury network (DILIN) is conducting a prospective study of patients with DILI in the United States. We present characteristics and subgroup analyses from the first 1257 patients enrolled in the study.
INTRODUCTION
Idiosyncratic drug induced liver injury (DILI) is a rare clinical event but it carries significant morbidity and mortality (1) (2) (3) . Its annual incidence in the general population ranges between 14 and 19 events per 100,000 inhabitants with nearly 30% exhibiting jaundice (4, 5) . It is one of the leading causes of acute liver failure in the United States (6, 7) and it continues to be an important barrier for new drug development and marketing (8) . The Drug Induced Liver Injury Network (DILIN), funded by the U.S. National Institutes of Health, is a consortium of several academic institutions and its overarching goal is to comprehensively investigate all aspects of DILI in both children and adults (9). The DILIN Prospective Study is an ongoing undertaking of the DILIN. It is an observational longitudinal study of individuals ≥ 2 years of age with suspected DILI (10) . Initiated in 2004, this study has led to several publications related to DILI (11) (12) (13) (14) (15) , including a summary of its initial 300 participants enrolled. The main findings of those studies were (a) antimicrobials and herbal or dietary supplements (HDS) were the major causes, (b) acute DILI carried an 8% risk of mortality and 13% risk of unresolved or chronic injury at 6 months following onset, and (C) acute hepatitis C and E can masquerade as DILI. Since that report, the DILIN Prospective Study has continued to enroll subjects, providing an opportunity to further characterize DILI in the United States in a large cohort of patients who were carefully followed and assessed in a standardized fashion.
The main objectives of this paper are to provide (a) summary description of subjects enrolled and their outcomes, (b) more detailed description and characterization of DILI caused by major therapeutic classes and individual agents in the United States, and (c) several notable aspects of DILI: like DILI in individuals with preexisting liver disease, in older persons, with short and very long latency, and associated with severe cutaneous reactions.
METHODS
A detailed description of the DILIN's enrollment and case ascertainment procedures has been published elsewhere (10) . Briefly, subjects considered for enrollment into the DILIN sign a written informed consent approved by the local institutional review board. Subjects are at least 2 years of age at the time of enrollment, and suspected of having experienced potential non-acetaminophen DILI within the preceding six months. Criteria for enrollment included jaundice (serum bilirubin ≥ 2.5 mg/dL) or coagulopathy (INR > 1.5) with any elevations in alanine or aspartate aminotransferase (ALT or AST) alkaline phosphatase (Alk P) levels; or, in the absence of jaundice or coagulopathy, elevations of ALT or AST above 5 times the upper limit of normal (ULN) or Alk P above 2 times ULN. The point at which these eligibility criteria were met was used as the definition of onset of hepatotoxicity (as opposed to time of onset of symptoms). At the baseline visit, study subjects were queried on the chronological use of all drugs and HDS. In addition, relevant clinical, biochemical, serological, imaging, and histological data were abstracted from the medical record and, if not already done, testing was performed for conditions that can mimic DILI, including serology for hepatitis A, B, C and E, CMV, EBV, HSV, and for autoimmune hepatitis. Subjects were asked to return for repeated testing at six months; if the serum chemistry values or hepatic imaging or examination remained abnormal at that time, the injury was regarded chronic, and follow-up was continued with visits at months 12 and 24. This information was assembled into a pre-defined dataset for the causality assessment process. It should be noted that some of the subjects included in this paper have been included in previous papers published by the DILIN. The liver histology findings from most of the patients contained in this paper who had a liver biopsy during their liver injury episode have been previously described (14) and thus are not included in this report.
Severity Assessment
Laboratory and clinical data were used to assign a disease severity score. Severity was scored as mild (1+) for serum enzyme elevations in the absence of jaundice (bilirubin < 2.5 mg/dL); moderate (2+) by jaundice (bilirubin ≥ 2.5 mg/dL) or coagulopathy (INR >1.5) without the need for hospitalization; moderately severe (3+) by jaundice or coagulopathy and need for hospitalization; severe (4+) by jaundice and signs of hepatic or other organ failure; and fatal (5+) by death from liver disease or the need for liver transplantation within six months of onset.
Causality Assessment
The causal relationship between the liver injury and the implicated drug or HDS was evaluated in a formal and standardized fashion by the DILIN Causality Committee as previously described (10) . Causality was assessed as either definite (>95% likelihood), highly likely (75-95%), probable (50-74%), possible (25-49%) or unlikely (<25%). In cases in which several agents were considered possibly implicated, the overall event was adjudicated for the likelihood that it was DILI, and then each agent was given a separate score, but only one agent was permitted to be considered as being highly likely or definitely responsible. Cases involving HDS products were often complex, in that multiple products were used and the components in the products were often varied and their concentration and nature were not always well defined. For this reason, HDS products (even when several were being taken) were adjudicated as a single agent at the time of this manuscript preparation. Agreement among the reviewers was achieved through email communications and teleconferences. Only cases of confirmed DILI (i.e. probable, highly likely or definite) were included in this report. The causality assessment for each case occurred 6 months after their enrollment which provided an opportunity to follow each case wherever possible for 6 months and this permitted better characterization of the relationship between the implicated agent and the liver injury event.
Assessment of Clinical Patterns of Liver Injury
Assessing the pattern of liver injury as hepatocellular, cholestatic, or mixed is based on calculating the "R" ratio, defined by the ratio of serum ALT to Alk P, both expressed as multiples of the ULN. By convention, an R ratio of >5 indicates hepatocellular, <2 cholestatic, and 2-5 mixed injury (16, 17) . The R ratio applied to each case was calculated based upon values at the onset of injury. In this study we also evaluated a modified R-ratio which was based on peak serum ALT and Alk P values, rather than their values at presentation.
Data Management and Statistical Analyses
Demographic and clinical data for subjects enrolled into the DILIN Prospective Study between September 2004 and May 2013 were extracted on May 16, 2013 . Descriptive statistics such as means with standard deviation, median with interquartile ratios and frequency distributions were used to describe the cohort. Between group difference were tested using the chi-square test for categorical variables and Wilcoxon/Kruskal-Wallis test for the continuous variables. All statistical analyses were performed using SAS version 9.2 (SAS Institute, Inc, Cary, NC). A p-value <0.05 was considered statistically significant.
RESULTS

Summary Description of Subjects Enrolled and their Outcomes
Between September 1, 2004 and May 16, 2013, 1257 subjects were enrolled into the DILIN Prospective Study. Among these, 1091 had been reviewed and adjudicated by a panel of expert hepatologists at the time of these analyses. The scores for likelihood of causality were definite in 235 (22%); highly likely in 466 (43%), probable in 198 (18%), possible in 142 (13%) and unlikely in 50 (5%). The common etiologies for liver injury among these 50 cases deemed as unlikely due to DILI are flare up of underlying liver disease due to hepatitis B or C, autoimmune hepatitis, unsuspected biliary obstruction, and multifactorial (e.g., multiple medication, sepsis, and transfusions), especially in those who were hospitalized. This analysis is limited to the 899 subjects with causality scores of definite, highly likely, or probable.
Among the 899 subjects with confirmed DILI, 56 (6%) died within 6 months of onset of whom 27 (48%) were considered to have died from liver failure related to the drug-induced injury. An additional 33 patients underwent liver transplantation (4%) within six months of onset. Thus, 10% of the subjects had a fatal outcome that was considered related to the DILI event. And additional 126 [17.5%] subjects had evidence of continuing liver injury after 6 months [subsequently termed "chronic DILI"]. Thus, almost a quarter of patients with DILI either died, underwent liver transplant or had residual liver injury at the time of six month follow up after onset.
Demographic and selected clinical information for the 899 subjects studied-comparisons by their pattern of liver injury
As shown in Table 1 , the pattern of liver injury was hepatocellular in 54%, and cholestatic or mixed in 23% each. Patients with hepatocellular DILI tended to be younger (p < 0.001), less likely to be clinically jaundiced, and to have higher ALT levels than patients with cholestatic or mixed injury. In addition, women were relatively over-represented in the hepatocellular cohort (65%) compared to the cholestatic or mixed group (51%). The socalled 'latency', that is the time from start of the implicated drug to the time of identification of abnormality laboratory tests was significantly longer in hepatocellular cases (median = 46 vs 31 days, p < 0.001). Immuno-allergic features (at least two of the three features of fever, rash, or absolute eosinophilia>500µL) were more frequent in cholestatic (16%) and mixed injury (18%) than hepatocellular cases (11%).
The time course of injury was significantly more protracted in cholestatic than in the mixed or hepatocellular cases. The distribution of DILI severity scores was dichotomous, in that hepatocellular cases had higher proportions that were mild (ALT elevations without jaundice) but also a higher frequency of fatal cases (liver related death or transplantation) than cases with the cholestatic or mixed injury patterns. Strikingly, patients classified as having mixed injury had milder disease overall with fewer liver-related deaths and no cases undergoing liver transplantation. While 18% of all patients had evidence of chronic or unresolved injury six months after onset (chronic DILI), this outcome was much more frequent among cholestatic cases (31%) than either hepatocellular (13%) or mixed-injury cases (14%). Thus, the pattern of liver injury at the onset of the clinical syndrome had implications for disease severity and outcome with hepatocellular cases more likely to be fatal but cholestatic cases more likely to be prolonged and result in chronic injury. Cases of mixed injury had the most favorable prognosis and outcomes.
Most frequently implicated classes of drugs and most frequently implicated individual drugs
The 899 cases were ultimately attributed to one or more of 190 different agents, including 145 due to HDS and 754 due to prescription drugs. A total of 189 prescription drugs were primary implicated agents for these 754 cases (Supplementary table 1) . Antimicrobials were by far the most common class of causative drugs, accounting for 408 [45%] instances (Table  2) . Indeed, among individual agents, the nine most commonly implicated agents were all antimicrobials, mostly antibiotics (Table 2 ). Of importance, herbal agents/dietary supplements [HDS] were the second most common group but only rare specific HDS agents were implicated more than once and none were in the top 25 implicated agents (data not shown). Other therapeutic classes of agents included cardiovascular drugs (88: 10%), central nervous system agents (82: 9%), antineoplastic drugs (49: 5%) and analgesics (33: 3%, largely nonsteroidal anti-inflammatory agents). A more detailed analysis of the spectrum of HDS products that cause liver injury in this cohort as well as the secular trends in HDSrelated liver injury is described in greater detail elsewhere (17) . Between initiation of the DILIN Prospective Study in 2004 and the most recent years of accrual of patients, the proportion of cases attributed to HDS has risen from approximately 7% to 17%.
A listing of all prescription drugs that were implicated as either definite, highly likely or probable in at least one DILI case is given in Supplementary Table 1 . The ten most commonly implicated non-HDS agents accounted for 25% of all cases and the 25 most common non-HDS agents accounted for half of all cases. The remaining half of cases were caused by agents implicated in only 1 or 2 cases. These results demonstrate the diversity of causes of DILI.
Comparisons among most frequent classes of agents and single agents
Among the five most frequent classes of prescription drugs (antimicrobials, cardiovascular agents, CNS agents, antineoplastic agents, analgesics), there were few clinical differences in the liver injury attributed to their use ( Table 3) . Most of the differences were attributable to differences in the types of patients who would receive these agents. Thus, those with liver injury from CNS agents were younger than subjects in the other cohorts (the major agents being anticonvulsants and antipsychotic medications). Not surprisingly, those with DILI due to anti-neoplastic agents were more likely to die within 12 months of onset and none underwent liver transplantation. Similarly, analyses of selected characteristics of DILI for the ten most frequent prescription drugs, also showed few notable differences (Supplemental Table 2 ). There were higher frequencies of increased eosinophil counts in DILI due to trimethoprim-sulfamethoxazole (31%), cefazolin (30%), ciprofloxacin (33%), all of which are known frequently to cause immuno-allergic liver injury (2) . There also were higher frequencies of high-titer ANA positivity in nitrofurantoin (52%) and minocycline (57%)-induced DILI; both of these drugs are well known to trigger auto-immune hepatitis in susceptible persons (2) . For other agents, ANA, when positive, had low titers and with frequencies similar to that observed in adult US population (18) . DILI due to analgesics was usually hepatocellular in nature; for example all 12 cases of diclofenac DILI were hepatocellular. Among the cases of analgesic DILI, there was only one death and no one required liver transplantation.
Pattern of liver injury according to a modified definition
The R-ratio which biochemically characterizes DILI is typically defined based on ALT and Alk P values at the time of onset. However, some patients present with a hepatocellular pattern of injury, but subsequently developed marked cholestasis. We therefore sought to assess the significance of using an R-ratio based on the peak ALT and peak Alk P values, which are often non-concurrent. According to this modified R-ratio, the proportion of hepatocellular (52%), cholestatic (25%) and mixed DILI (23%) were largely unchanged. Furthermore, the clinical and biochemical characteristics and outcomes of hepatocellular, cholestatic and mixed DILI were not different between two definitions of the R-ratio (data not shown). Using the modified R-ratio, 5 cholestatic cases were reclassified as hepatocellular, and 8 originally hepatocellular cases were reclassified as cholestatic.
Selected characteristics among the elderly (≥ 65 years) compared to younger subjects (< 65 years)
The demographic and clinical features of DILI were generally similar in older and younger participants ( Table 4 ). The most striking differences were the higher proportion of cholestatic pattern of injury among the elderly (36% vs 21%, p < 0.001) with significantly higher levels of serum Alk P (at onset, mean, 410 vs 264; at peak 520 vs 383 U/L, p for both < 0.001). The severity of liver injury was somewhat lower in the elderly group (p=0.08) as was the frequency of chronic DILI (11% vs 19%, p =0.04).
Nine subjects with severe cutaneous adverse reactions
As summarized in Table 5 , six subjects exhibited features of Stevens Johnson Syndrome (SJS) and 3 had toxic epidermal necrolysis (TEN) (1%). The implicated agents were lamotrigine (n=2), azithromycin (n=2), carbamazepine (n=1), moxifloxacin [1] , cephalexin (n=1), diclofenac (n=1), and nitrofurantoin [1] . The pattern of liver injury was hepatocellular in 7 and mixed in 2 patients. In keeping with the known high severity of illness in SJS, four of the nine individuals died and an additional individual developed chronic injury, in a pattern suggestive of vanishing bile duct syndrome.
DILI in underlying liver disease
Eighty-nine [10%) subjects with DILI had known pre-existing chronic liver disease, mainly hepatitis C (n=36) and nonalcoholic fatty liver disease or unexplained elevations in liver biochemistries (n=47). Demographic and clinical features of this cohort were generally similar to those of patients without known underlying chronic liver disease (Table 6 ). There were no significant differences in the classes of agents to cause DILI in the pre-existing liver group (p=0.2) and the top 5 classes of agents were antimicrobials (51%), HDS (13.5%), cardiovascular agents (7%), antineoplastic agents (6%) and CNS agents (4.5%). A full listing of all implicated agents in individuals with underlying chronic liver disease is shown in Supplemental Table 3 . Commonly implicated agents were isoniazid (n=7), azithromycin (n=6), amoxicillin-clavulanate (n=4) and nitrofurantoin (n=4). Interestingly, azithromycin was the implicated agent in a higher proportion of patients with pre-existing liver disease compared to those without liver disease (6.7% vs. 1.5%, p=0.006). Individuals with preexisting liver disease also had a higher prevalence of diabetes [38% vs 23%, p = 0.004]. There was a trend for levels of serum ALT and Alk P to be lower in those with pre-existing liver disease, but serum total bilirubin and INR were not different. There were differences in the causality scores with fewer cases of definite DILI in individuals with pre-existing liver disease (p=0.009). Severity of the liver injury tended to be higher in those with pre-existing liver disease but this did not reach statistical significance (p=0.09). Importantly, there was higher mortality in those with pre-existing liver disease [16% vs 5.2%, p < 0.001].
Short (≤ 7 days) vs long latency DILI (> 365 days)
We examined whether there were differences between subjects and their clinical courses, depending upon the 'latency', the number of days between the start of the causative medication and onset of laboratory evidence of DILI (Table 7) . There were 41 short-latency DILI cases (4.5%) and the most commonly implicated agents were moxifloxacin (n=4), azithromycin (n=3), ciprofloxacin (n=3), rifampin (n=2), and levofloxacin (n=2). However, there were 60 cases with long latency (6.7%) and the most commonly implicated agents were nitrofurantoin (n=16), minocycline (n=10), statins (n=4), amiodarone (n=3), mercaptopurine (n=3), atomoxetine (n=2), tamoxifen (n=2), oxaliplatin (n=2) and interferonbeta (n=2). The frequencies of different patterns of liver injury and profile of liver biochemistries were not different between the two groups. There were trends for slower resolution of DILI and a trend toward higher likelihood of chronic DILI in those with long latency (31% vs 12.5%, p= 0.07) but the rates of death or liver transplantation were not different.
DISCUSSION
The DILIN Prospective Study initiated in 2004 has resulted in several important papers published previously. These include the characteristics of initial 300 patients enrolled (11), natural history of DILI (15) liver histology of DILI (14) , DILI in children (20) , DILI caused by intravenous agents (21) , and DILI caused by selected agents (e.g., duloxetine (22) , flavocoxid (13), interferon-beta (23), quinolones (24) . The current paper with by far the largest number of prospectively characterized cases of DILI reports several findings which have not been reported previously in the literature.
Some novel aspects of this report are description of DILI (a) in the elderly, (b) occurring in individuals with underlying chronic liver disease, (c) with very short and long latency, and (d) associated severe cutaneous reactions. In addition, it describes temporal trends in the causative agents of DILI over the last decade and also provides a detailed comparison of characteristics of DILI caused by most common therapeutic classes and individual agents.
Older age is not necessarily a risk factor for all-cause DILI but elderly individuals may be higher risk for DILI caused by specific compounds such as amoxicillin-clavulanate (25), isoniazid (26, 27) and nitrofurantoin (28) . Furthermore, it previously has been described that cholestatic DILI is more common in the elderly whereas younger individuals are more likely to present with hepatocellular DILI (29) . This study consisting of a large number of individuals who are ≥ 65 years of age indeed confirms that the pattern of their liver injury is more likely to be cholestatic than in individuals who are < 65 years of age. It is unclear if there is a biological basis for such a difference in the phenotype or if it is a reflection of causative agents for DILI in the elderly. In fact, there is significantly highly representation of antimicrobials in the elderly individuals (57.5% vs. 43%, p=0.047) and antimicrobials such as amoxicillin-clavulanate are known to predominantly cause cholestatic DILI. Although there was more cholestatic DILI which is generally associated with higher likelihood of chronic DILI, the frequency of chronic DILI in the elderly in this cohort was significantly lower than in those who are < 65 years of age. This may in part be due to lower prevalence of DILI caused by anabolic steroids in the elderly group which are known to cause prolonger cholestasis and higher likelihood of chronic DILI. Despite their older age and polypharmacy, elderly group did not have higher frequency of liver transplantation or death.
Some patients with DILI are known to present with severe cutaneous reactions such as SJS and TEN but its causative agents and clinical characteristics are not well defined. The 1% prevalence of SJS/TEN in this cohort is significantly lower than 7.7% prevalence in pediatric DILI reported from India (30) . In this report from India, out of 39 children with DILI, three developed SJS/TEN due to phenytoin (n=2) and carbamazepine (n=1). Interestingly, there were no instances of SJS or TEN among 96 cases of DILI reportedly recently from Iceland (5) (Personal communication, Prof. Einar Bjornsson, Reykjavik, Iceland) . In our experience, lamotrigine and azithromycin were the two common causes of DILI with severe skin adverse reactions, with a frequency of 22% for lamotrigine DILI (2 out of 9 definite/highly likely/probable lamotrigine DILI cases) and 11% for azithromycin DILI (2 out of 18 definite/highly likely/probably azithromycin DILI cases). Drugs commonly described as at risk for causing severe cutaneous drug reactions are nevirapine, lamotrigine, carbamapezine, phenytoin, phenobarbital, trimethoprim-sulfamethaxozole and another anti-infective sulfonamides, allopurinol, oxicam NSAIDs, aminopencillins, cephalosporins and quinolones (31) . Mortality rate for SJS/TEN in our series was 44% with 3 out of 4 deaths occurring during the acute episode whereas one 10 year old child who developed bronchiolitis obliterans and died subsequently due to respiratory failure. The high mortality rate observed in this series is generally consistent with 25-30% mortality rate described for severe cutaneous adverse reactions (32) .
It has been stated that patients with chronic liver disease and cirrhosis are not necessarily at risk for all-cause DILI, but it is likely that when an event of DILI occurs they may be at higher risk for adverse outcomes such as liver failure or death (33) . However, a systematic evaluation of etiologic agents, clinical characteristics and outcomes of DILI in individuals with preexisting chronic liver disease has been lacking. We found no enrichment of any particular therapeutic class in the liver disease group but interestingly there was significant enrichment of azithromycin DILI in individuals with preexisting chronic liver disease. It is unclear if individuals with underlying liver disease are at higher risk for DILI due to azithromycin or this phenomenon is merely a reflection of its higher usage in this patient population due to its presumed safety. It is noteworthy that we did not find higher prevalence of INH DILI in the liver disease cohort (6.7% in liver disease vs 5.2% in the nonliver disease group, p=0.5) but this could reflect lower usage of INH in individuals with preexisting liver disease. Higher mortality rate noted in the liver disease group supports the existing dictum that DILI events in individuals with chronic liver disease leads to higher adverse outcomes.
It is noteworthy that individuals who were ≥ 65 years of age had significantly higher incidence of Hy's law and yet their mortality was not significantly different from those who were under 65 years ago. The reason for discrepancy is unclear but we observed a similar pattern with DILI suspected due to diclofenac where there was 42% incidence of Hy's law and yet there were no deaths attributable to liver injury. This raises the possibility that the relationship between Hy's law and mortality due to hepatocellular DILI may depend on the compound implicated. More work is needed in this area to further clarify this issue.
There are many examples in the literature of instances of DILI occurring either with short (<7 days) or after long (>6-12 months) latency but a systematic evaluation of etiologic agents and characteristics of DILI with short and long latency has previously not been conducted. Contrary to our expectation, there was not significantly higher frequency of hypersensitivity features among DILI cases with short latency but 2 out of 9 DILI cases with SJS/TEN had short latency (Table 5) . Although nitrofurantoin and minocycline are the two dominant causes of DILI with long latency, a number of other medications such as 6-mercaptopurine, statins and amiodarone are also associated with DILI after prolonged latency. The knowledge that sometimes DILI can occur after long latency may prevent the clinicians from missing a diagnosis of DILI with catastrophic consequences.
An observation that we made in our initial report in 2008 about relatively lower frequency of serious adverse outcomes in mixed DILI continues to hold true in this paper (11) . The 5.4% frequency of death and transplantation in individuals with mixed DILI was lower than 11.6% and 11.9% frequency of death and transplantation in individuals with hepatocellular and cholestatic DILI respectively.
Limitations of our study include inherent selection bias, arbitrary laboratory eligibility criteria and lack of established standards for diagnosing DILI. The biochemical criteria we used in this study are largely consistent with recent case definitions proposed by an international panel of experts. DILI is a diagnosis of exclusion based on appropriate clinical history of medication exposure and thorough work up for competing etiologies. Each case was carefully and consistently adjudicated in a structured fashion by experienced hepatologists (10) . Since our study is not population based, one needs to exercise cautious in interpreting the reported temporal trends of HDS DILI. Higher representation of HDS during later years of our study may simply be a function of higher capture rather than higher incidence of HDS DILI.
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Abbreviations
Alk P
Alkaline phosphatase
ALT
Alanine aminotransferase
ANA
Anti-nuclear antibody
AST
Aspartate aminotransferase
Chol Cholestatic 49 [17] 45 [17] 54 [16] 50 [17] < 0.001 Table 2 Top ten therapeutic classes and individual agents to cause DILI in the DILIN Prospective Study Table 3 Comparison of selected characteristics of DILI due to top 5 classes of prescription agents Table 5 Characteristics Abbreviations: ALT, serum alanine aminotransferase; AP, serum alkaline phosphatase; BMI, body mass index; Chol, Cholestatic; DILI, druginduced liver injury; HC, hepatocellular; INR, international normalized ratio; IQR, interquartile range; SD, standard deviation; AMX, sulfamethoxazole; TMP, trimethoprim; ULN, upper limit of normal.
DILI
Drug-Induced liver injury
DILIN
Drug-Induced Liver Injury Network
HC Hepatocellular
HDS
Herbal and dietary supplement
IQR
Interquartile range
NIDDK
* Implicated HDS agents in 3 cases with short latency were (a) multiple CAM products -Extenze, AMP muscle building formula; (2) Multiple CAM products -Bulgarian mushrooms, Aloe Vera, Boldo tea; and (3) Meganite
